Skip to content
Brand AI

Dian Diagnostics

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2023

    Dian Diagnostics and chairman warned by Zhejiang CSRC Bureau over overdue return of RMB 50 million idle raised funds used for working capital

    Dian Diagnostics returned RMB 50 million in idle raised funds that had been temporarily used to supplement working capital only 11 days after the 12-month deadline; the Zhejiang CSRC Bureau issued warning letters to the company, chairman and general manager Chen Haibin, CFO Zhao Dekang, and board secretary Tao Jun and recorded them in the integrity file; the Shenzhen Stock Exchange also issued ChiNext Regulatory Letter [2023] No. 149. Status: regulatory measures. Entities involved: Dian Diagnostics Technology Group Co., Ltd., Chen Haibin, Zhao Dekang, and Tao Jun. Scope: raised funds management.

    Source